Loading...

SVRA SAVARA INC US FDA Inspections 8-K Filing

SVR

SVR

SAVARA INC

(SVRA)

2025 8-K

Show Summary

Summary

Pre-Market Approval

Agreement Termination

Executive Bonuses

Corporate Presentation

Underwriting Agreement

Clinical Trial Results

Amendment to Form 8-K

Amendment and Board Election

Departure of Director and W...

Agreement with Fujifilm Dio...

Compensation Committee Appr...

Regulation FD Disclosure

Annual Meeting of Stockholders

Regulation FD Disclosure

Amended Bylaws Adoption

Closure of Silicon Valley Bank

Amendment to Lease Agreement

Appointment of Chief Operat...

External Links:

On May 27, 2025, Savara Inc. announced that the U.S. FDA refused to file their application for molgramostim inhalation solution, intended to treat pulmonary alveolar proteinosis.

AI Assistant

SAVARA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.